AbbVie Inc. (ABBV) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
55/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinABBV / S&P 16.66% / 15.20% |
LoseABBV / S&P 10.39% / 15.00% |
WinABBV / S&P 68.57% / 50.40% |
| 2026-Q11/3 |
WinABBV / S&P -4.05% / -4.33% |
LoseABBV / S&P 9.50% / 11.30% |
LoseABBV / S&P -13.62% / 27.70% |
| 2025-Q40/3 |
LoseABBV / S&P -0.61% / 2.65% |
LoseABBV / S&P 8.57% / 9.00% |
LoseABBV / S&P -1.67% / 13.40% |
| 2025-Q32/3 |
WinABBV / S&P 25.82% / 8.12% |
WinABBV / S&P 7.40% / 4.61% |
LoseABBV / S&P -54.17% / 13.45% |
| 2025-Q21/3 |
LoseABBV / S&P -10.59% / 10.94% |
WinABBV / S&P 6.05% / 4.83% |
LoseABBV / S&P -30.00% / 10.63% |
| 2025-Q12/3 |
WinABBV / S&P 19.02% / -4.27% |
WinABBV / S&P 5.45% / 4.98% |
LoseABBV / S&P -30.27% / 10.57% |
| 2024-Q40/3 |
LoseABBV / S&P -9.30% / 2.41% |
LoseABBV / S&P 3.71% / 5.25% |
LoseABBV / S&P -12.09% / 6.15% |
| 2024-Q31/3 |
WinABBV / S&P 16.19% / 5.89% |
LoseABBV / S&P 0.72% / 5.89% |
LoseABBV / S&P -21.31% / 6.11% |
| 2024-Q20/3 |
LoseABBV / S&P -4.93% / 4.28% |
LoseABBV / S&P -1.83% / 5.38% |
LoseABBV / S&P -38.40% / 5.12% |
| 2024-Q11/3 |
WinABBV / S&P 18.63% / 10.56% |
LoseABBV / S&P -4.12% / 5.71% |
LoseABBV / S&P -20.52% / 5.59% |
| 2023-Q40/3 |
LoseABBV / S&P 5.01% / 11.69% |
LoseABBV / S&P -6.44% / 6.81% |
LoseABBV / S&P -58.76% / 7.78% |
| 2023-Q31/3 |
WinABBV / S&P 11.86% / -3.27% |
LoseABBV / S&P -4.64% / 7.52% |
LoseABBV / S&P -51.13% / -5.03% |
| 2023-Q20/3 |
LoseABBV / S&P -14.68% / 8.74% |
LoseABBV / S&P -2.31% / 9.50% |
LoseABBV / S&P -31.02% / -8.57% |
| 2023-Q10/3 |
LoseABBV / S&P -0.45% / 7.50% |
LoseABBV / S&P 0.03% / 10.77% |
LoseABBV / S&P -39.17% / -15.69% |
| 2022-Q42/3 |
WinABBV / S&P 21.64% / 7.56% |
LoseABBV / S&P 3.30% / 11.88% |
WinABBV / S&P 2.64% / -17.99% |
| 2022-Q31/3 |
LoseABBV / S&P -11.55% / -4.88% |
LoseABBV / S&P 4.80% / 13.47% |
WinABBV / S&P 80.92% / -1.41% |
| 2022-Q22/3 |
WinABBV / S&P -4.72% / -16.10% |
LoseABBV / S&P 6.74% / 13.71% |
WinABBV / S&P 93.42% / 11.04% |
| 2022-Q12/3 |
WinABBV / S&P 20.97% / -4.60% |
LoseABBV / S&P 13.01% / 15.97% |
WinABBV / S&P 151.62% / 42.23% |
| 2021-Q43/3 |
WinABBV / S&P 27.04% / 11.03% |
WinABBV / S&P 22.69% / 15.00% |
WinABBV / S&P 130.36% / 96.40% |
| 2021-Q31/3 |
LoseABBV / S&P -3.17% / 0.58% |
WinABBV / S&P 35.72% / 10.77% |
LoseABBV / S&P -12.29% / 69.42% |
| 2021-Q21/3 |
LoseABBV / S&P 5.35% / 8.55% |
WinABBV / S&P 48.31% / 6.58% |
LoseABBV / S&P -22.17% / 51.81% |
| 2021-Q11/3 |
LoseABBV / S&P 2.18% / 6.17% |
WinABBV / S&P 47.39% / -1.06% |
LoseABBV / S&P -50.89% / 7.39% |
| 2020-Q42/3 |
WinABBV / S&P 24.00% / 12.15% |
WinABBV / S&P 37.69% / -3.72% |
LoseABBV / S&P -46.87% / -33.42% |
| 2020-Q32/3 |
LoseABBV / S&P -9.70% / 8.93% |
WinABBV / S&P 23.68% / -2.04% |
WinABBV / S&P 107.93% / -27.10% |
| 2020-Q23/3 |
WinABBV / S&P 30.78% / 20.54% |
WinABBV / S&P 11.04% / -0.46% |
WinABBV / S&P 66.31% / -27.11% |
| 2020-Q13/3 |
WinABBV / S&P -12.79% / -19.60% |
WinABBV / S&P 4.32% / 3.47% |
WinABBV / S&P 57.10% / -14.75% |
| 2019-Q42/3 |
WinABBV / S&P 18.64% / 9.07% |
LoseABBV / S&P 1.57% / 5.36% |
WinABBV / S&P 43.21% / 2.99% |
| 2019-Q31/3 |
WinABBV / S&P 5.71% / 1.70% |
LoseABBV / S&P 2.11% / 5.02% |
LoseABBV / S&P -53.10% / 0.21% |
| 2019-Q20/3 |
LoseABBV / S&P -8.57% / 4.30% |
LoseABBV / S&P 5.42% / 6.64% |
LoseABBV / S&P -30.20% / 8.65% |
| 2019-Q11/3 |
LoseABBV / S&P -11.51% / 13.65% |
WinABBV / S&P 10.25% / 8.12% |
LoseABBV / S&P -9.57% / 14.29% |
| 2018-Q42/3 |
WinABBV / S&P -1.48% / -13.52% |
WinABBV / S&P 16.08% / 9.05% |
LoseABBV / S&P 11.85% / 18.23% |
| 2018-Q31/3 |
LoseABBV / S&P 3.13% / 7.71% |
WinABBV / S&P 18.02% / 10.21% |
LoseABBV / S&P 17.76% / 19.06% |
| 2018-Q21/3 |
LoseABBV / S&P -1.10% / 3.43% |
WinABBV / S&P 15.86% / 9.03% |
LoseABBV / S&P -0.74% / 14.46% |
| 2018-Q11/3 |
LoseABBV / S&P -1.43% / -0.76% |
WinABBV / S&P 12.95% / 7.68% |
LoseABBV / S&P 2.85% / 12.46% |
| 2017-Q42/3 |
WinABBV / S&P 9.59% / 6.64% |
WinABBV / S&P 10.06% / 7.03% |
LoseABBV / S&P -9.37% / 13.82% |
| 2017-Q32/3 |
WinABBV / S&P 23.65% / 4.48% |
WinABBV / S&P 8.05% / 5.68% |
LoseABBV / S&P 11.08% / 17.57% |
| 2017-Q22/3 |
WinABBV / S&P 12.39% / 3.09% |
WinABBV / S&P 7.90% / 4.83% |
LoseABBV / S&P 17.29% / 17.74% |
| 2017-Q12/3 |
LoseABBV / S&P 5.11% / 6.07% |
WinABBV / S&P 10.27% / 3.67% |
WinABBV / S&P 16.27% / 13.32% |
| 2016-Q42/3 |
LoseABBV / S&P 0.20% / 3.82% |
WinABBV / S&P 12.16% / 2.09% |
WinABBV / S&P 16.35% / 7.05% |
| 2016-Q32/3 |
LoseABBV / S&P 2.77% / 3.85% |
WinABBV / S&P 15.20% / 0.20% |
WinABBV / S&P 117.65% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ABBV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 26.50% | 20.78% |
| Annualized return | 26.50% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ABBV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 176.25% | 83.14% |
| Annualized return | 22.54% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ABBV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 507.77% | 319.30% |
| Annualized return | 19.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |